{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:40:25Z","timestamp":1788205225612,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome. Acute cerebellar syndrome may occur, which can be explained by the extremely high accumulation of the drug in the cerebellum. However, presentation mimicking neuroleptic malignant syndrome similar to our case has never been reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Here, we describe a 68-year-old Thai male presenting with advanced-stage cecal adenocarcinoma, as well as symptoms and signs indicative of neuroleptic malignant syndrome. He received two doses of intravenous metoclopramide 10\u00a0mg 6\u00a0hours before his symptoms occurred. Magnetic resonance imaging scan revealed signal hyperintensity within the bilateral white matter. Further evaluation showed that his thiamine level was extremely low. Thus, he was diagnosed with fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome. The concomitant fluorouracil-induced thiamine deficiency eventually leads to rapid depletion of thiamine and was considered a risk factor for fluorouracil-induced leukoencephalopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Fluorouracil-induced leukoencephalopathy is believed to be caused by insult causing mitochondrial dysfunction. However, the exact mechanism remains unknown, but our finding suggests that thiamine deficiency plays a crucial role in fluorouracil-induced leukoencephalopathy. Diagnosis is usually delayed due to a lack of clinical suspicion and results in significant morbidity requiring unnecessary investigations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03814-3","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:19:55Z","timestamp":1680740395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-3475","authenticated-orcid":false,"given":"Pasin","family":"Hemachudha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanakorn","family":"Rattanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakit","family":"Pongpitakmetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warongporn","family":"Phuenpathom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"7","key":"3814_CR1","first-page":"1735","volume":"33","author":"RS Bourke","year":"1973","unstructured":"Bourke RS, et\u00a0al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res. 1973;33(7):1735\u201346.","journal-title":"Cancer Res"},{"issue":"7690","key":"3814_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0140-6736(71)90877-4","volume":"1","author":"JA Gottlieb","year":"1971","unstructured":"Gottlieb JA, Luce JK. Cerebellar ataxia with weekly 5-fluorouracil administration. Lancet. 1971;1(7690):138\u20139.","journal-title":"Lancet"},{"key":"3814_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1212\/WNL.14.10.961","volume":"14","author":"JL Riehl","year":"1964","unstructured":"Riehl JL, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology. 1964;14:961\u20137.","journal-title":"Neurology"},{"issue":"6","key":"3814_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/0002-9394(77)90904-7","volume":"83","author":"WW Bixenman","year":"1977","unstructured":"Bixenman WW, Nicholls JV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol. 1977;83(6):789\u201393.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3814_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1020613600826","volume":"60","author":"L Delval","year":"2002","unstructured":"Delval L, Klastersky J. Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature. J Neurooncol. 2002;60(2):165\u20139.","journal-title":"J Neurooncol"},{"issue":"2","key":"3814_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1005791623733","volume":"34","author":"A Brashear","year":"1997","unstructured":"Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol. 1997;34(2):163\u20137.","journal-title":"J Neurooncol"},{"issue":"3","key":"3814_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1212\/WNL.51.3.899","volume":"51","author":"M El Amrani","year":"1998","unstructured":"El Amrani M, et\u00a0al. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology. 1998;51(3):899\u2013901.","journal-title":"Neurology"},{"issue":"2","key":"3814_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.01.014","volume":"23","author":"R Kinno","year":"2014","unstructured":"Kinno R, et\u00a0al. 5-Fluorouracil-induced leukoencephalopathy with acute stroke-like presentation fulfilling criteria for recombinant tissue plasminogen activator therapy. J Stroke Cerebrovasc Dis. 2014;23(2):387\u20139.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"3814_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/070674378603100715","volume":"31","author":"A Lazarus","year":"1986","unstructured":"Lazarus A. The neuroleptic malignant syndrome: a review. Can J Psychiatry. 1986;31(7):670\u20134.","journal-title":"Can J Psychiatry"},{"issue":"10","key":"3814_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","volume":"142","author":"JL Levenson","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137\u201345.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"3814_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/biology10090854","volume":"10","author":"S Azwar","year":"2021","unstructured":"Azwar S, et\u00a0al. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology. 2021;10(9):854.","journal-title":"Biology"},{"issue":"4","key":"3814_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/jbiol69","volume":"7","author":"R Han","year":"2008","unstructured":"Han R, et\u00a0al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7(4):12.","journal-title":"J Biol"},{"issue":"3","key":"3814_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/bjc.1997.79","volume":"75","author":"KH Yeh","year":"1997","unstructured":"Yeh KH, Cheng AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer. 1997;75(3):464\u20135.","journal-title":"Br J Cancer"},{"issue":"22","key":"3814_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006874","volume":"96","author":"S Mitani","year":"2017","unstructured":"Mitani S, et\u00a0al. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature. Medicine (Baltimore). 2017;96(22): e6874.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3814_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/jjco\/hyi214","volume":"36","author":"YA Kim","year":"2006","unstructured":"Kim YA, et\u00a0al. Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol. 2006;36(1):55\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"3814_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2131\/jts.43.727","volume":"43","author":"S Yamada","year":"2018","unstructured":"Yamada S, Yamazaki D, Kanda Y. 5-Fluorouracil inhibits neural differentiation via Mfn1\/2 reduction in human induced pluripotent stem cells. J Toxicol Sci. 2018;43(12):727\u201334.","journal-title":"J Toxicol Sci"},{"issue":"4","key":"3814_CR17","first-page":"1073","volume":"9","author":"MS Heier","year":"1989","unstructured":"Heier MS, Dornish JM. Effect of the fluoropyrimidines 5-fluorouracil and doxifluridine on cellular uptake of thiamin. Anticancer Res. 1989;9(4):1073\u20137.","journal-title":"Anticancer Res"},{"key":"3814_CR18","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.19126","author":"Y Yano","year":"2020","unstructured":"Yano Y, Kuriyama A. 5-Fluorouracil-induced encephalopathy. Cleve Clin J Med. 2020. https:\/\/doi.org\/10.3949\/ccjm.87a.19126.","journal-title":"Cleve Clin J Med"},{"key":"3814_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-022-00117-4","author":"N Jose","year":"2022","unstructured":"Jose N, et\u00a0al. Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single\u2014centre case series. J Egypt Natl Cancer Inst. 2022. https:\/\/doi.org\/10.1186\/s43046-022-00117-4.","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"30","key":"3814_CR20","doi-asserted-by":"publisher","first-page":"11376","DOI":"10.1073\/pnas.0600768103","volume":"103","author":"VI Pidoplichko","year":"2006","unstructured":"Pidoplichko VI, Dani JA. Acid-sensitive ionic channels in midbrain dopamine neurons are sensitive to ammonium, which may contribute to hyperammonemia damage. Proc Natl Acad Sci U S A. 2006;103(30):11376\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3814_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.272","author":"J Lukaschek","year":"2004","unstructured":"Lukaschek J, et\u00a0al. Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials. J Clin Oncol. 2004. https:\/\/doi.org\/10.1200\/JCO.2004.04.272.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3814_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","volume":"123","author":"WW Ma","year":"2017","unstructured":"Ma WW, et\u00a0al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123(2):345\u201356.","journal-title":"Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03814-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03814-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03814-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:19:57Z","timestamp":1680740397000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03814-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03814-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for reporting individual cases or case series, and consent for participation in the case report has been obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no relevant disclosures or competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}